In February of 2006, Biomachines Inc was acquired by Clearview Limited. BioMachines' technology platform addresses proteomic bottlenecks, such as 2D Gel Processing, Biochip Fabrication and Analysis, and Small Volume Liquid Handling. BioMachines' bench-top instrumentation and consumable platform will scale from the research laboratory to clinical drug development and analysis, providing an automated and integrated solution while maintaining clinical quality standardization and full traceability
